



20 April 2022

Clinical Trial Results; No Subjects Enrolled in UK or EU/EEA

EudraCT: 2018-003093-27

To whom it may concern,

On behalf of the Sponsor, GB002, Inc., we wish to notify you that, for the clinical trial described below, although a EudraCT number was assigned and MHRA approval was granted (MHRA ref; 55555-0001-001), no subjects were enrolled in the United Kingdom or European Union.

Furthermore, this investigational medicinal product (seralutinib, also known as GB002) does not have a marketing authorization in the EU/UK and is not the subject of any ongoing MAA procedure.

Therefore, GB002, Inc. will not be submitting study results to EudraCT for the study described below.

EudraCT number	Sponsor code	Title
2018-003093-27	GB002-1101	A Phase 1b, Randomized, Subject- And Investigator Blinded, Placebo-Controlled, Multi-Center Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Biomarkers of Inhaled Gb002 in Subjects with WHO Group 1 Pulmonary Arterial Hypertension (PAH)

Please contact me if you require any additional information.

Yours sincerely,

DocuSigned by:

Conor O'Donovan



Signer Name: Conor O'Donovan

Signing Reason: I approve this document

Signing Time: 26-Apr-22 | 3:26 AM PDT

Conor O'Donovan

B6703E7BCB2D4CA1B952922FE9CE3D9B
Executive Director, Regulatory Affairs

Gossamer Bio 002 Limited, on behalf of GB002, Inc.

+353-1-526-9881

codonovan@gossamerbio.com